Posts

Cerevance reports Phase 3 win for experimental Parkinson’s drug

on
On October 7, 2026, Cerevance reported positive topline results from the Phase 3 ARISE trial of solengepras, an experimental once-daily oral Parkinson’s treatment taken alongside levodopa and other standard medications. The 150 mg dose met the primary endpoint: at Week 12, daily “OFF” time—when symptoms return or worsen as medication wears off—fell by 1.56 hours from baseline, versus 0.95 hours with placebo. The placebo-adjusted difference was 0.61 hours, or about 37 minutes (p=0.035). The company also reported improvements in ON time without troublesome dyskinesia and motor activities of daily living. It highlighted potential daytime-sleepiness and quality-of-life benefits as additional findings. Cerevance said solengepras was generally well tolerated; detailed results and further review will be important to understand the safety and size of the benefit. The company plans to discuss the results with the U.S. FDA and determine a path toward a possible New Drug Application. So...

GLP-1 boom pushes drugmakers to market to consumers

on

Five of the biggest venture capital raises of Q3 2026

on

Forbion raises record €2.3 billion with Eli Lilly among its backers

on

ArriVent lung cancer drug misses Phase 3 target

on

AstraZeneca opens major R&D centre in Cambridge, Massachusetts

on

Caribou halts CAR-T programs and weighs strategic options after funding shortfall

on

PulseSight reports preliminary PST-611 signals in a six-person Phase I study

on

Epkinly posts a first-line DLBCL trial win—but “best” remains unproven

on

Formycon expands AI and digital tools across biosimilar development

on

Shionogi agrees to buy IntraBio for $2 billion

on

BioSpace 40 Under 40 winners make their mark on biopharma

on

Shionogi to acquire IntraBio for $2 billion, expanding rare-disease portfolio

on